Hybrid Effectiveness-Implementation Study to Improve Clopidogrel Adherence

NACompletedINTERVENTIONAL
Enrollment

14,573

Participants

Timeline

Start Date

January 20, 2014

Primary Completion Date

March 1, 2018

Study Completion Date

February 7, 2022

Conditions
Cardiovascular DiseaseAcute Coronary Syndrome
Interventions
OTHER

Multifaceted Intervention with pharmacist and IVR

An alerted inpatient pharmacists will bring the clopidogrel medication to the patient who has received a stent. The patient will return home and receive IVR messages about the importance of their medication as well as a refill reminder call.

Trial Locations (15)

10010

Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY, New York

20422

Washington DC VA Medical Center, Washington, DC, Washington D.C.

24153

Salem VA Medical Center, Salem, VA, Salem

27705

Durham VA Medical Center, Durham, NC, Durham

30033

Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur

32608

North Florida/South Georgia Veterans Health System, Gainesville, FL, Gainesville

39216

G.V. (Sonny) Montgomery VA Medical Center, Jackson, MS, Jackson

44106

Louis Stokes VA Medical Center, Cleveland, OH, Cleveland

45220

Cincinnati VA Medical Center, Cincinnati, OH, Cincinnati

48105

VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor

73104

Oklahoma City VA Medical Center, Oklahoma City, OK, Oklahoma City

77030

Michael E. DeBakey VA Medical Center, Houston, TX, Houston

80045

Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora

52246-2208

Iowa City VA Health Care System, Iowa City, IA, Iowa City

87108-5153

New Mexico VA Health Care System, Albuquerque, NM, Albuquerque

All Listed Sponsors
lead

VA Office of Research and Development

FED

NCT01609842 - Hybrid Effectiveness-Implementation Study to Improve Clopidogrel Adherence | Biotech Hunter | Biotech Hunter